Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 30.03.2026 1 AJR Am J Roentgenol 1 Am J Gastroenterol 3 Am J Pathol 1 Biochem Biophys Res Commun 2 BMC Cancer 1 BMC Gastroenterol 1 Cancer Res 1 Eur J Pediatr 5 Gastroenterology 1 Hepatology 4 Indian J Gastroenterol 2 J Gastroenterol 4 J Gastroenterol Hepatol 2 J Hepatol 1 N Engl J Med 1 Oncogene 3 PLoS One 3 Radiology 1 Semin Liver Dis 3 Transplant Proc 2 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. 
   Correction for: "LI-RADS Ultrasound Surveillance Version 2024: Comparison With Version 2017 for Hepatocellular Carcinoma Detection and Risk Factors for Visualization Score C".
   AJR Am J Roentgenol. 2026 Mar 25:1. doi: 10.2214/AJR.25.34490.
   PubMed        
   
   

   
   Am J Gastroenterol

2. JOHNSON PJ, Kalyuzhnyy A, Grauslys A, Toyoda H, et al
   Predicting the Risk of Decompensation in Patients with Cirrhosis - a Validated Machine Learning Approach.
   Am J Gastroenterol. 2026 Mar 25. doi: 10.14309/ajg.0000000000004004.
   PubMed         Abstract available
   
   

   
   Am J Pathol

3. ZHANG J, Zhou J, Shen X, Li Y, et al
   Cuproptosis Is Induced in Drug-Induced Liver Injury by Oxidative Stress-Mediated Copper Overload.
   Am J Pathol. 2026;196:868-882.
   PubMed         Abstract available
   
   
4. LIANG C, Chen X, Wang X, Tang J, et al
   Gpat3 knockout attenuates adipose loss and steatohepatitis in Agpat2-deficient mice.
   Am J Pathol. 2026 Mar 23:S0002-9440(26)00069.
   PubMed         Abstract available
   
   
5. CHEN H, Yang M, Tu X, Li J, et al
   Notch1-Gli1 axis reprograms macrophage polarization and promotes hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis.
   Am J Pathol. 2026 Mar 19:S0002-9440(26)00063.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. YE F, Sun Y, Pan J
   Purpurogallin improves septic coagulopathy and hepatic injury through inhibiting AKT/mTOR/STAT3 signaling pathway.
   Biochem Biophys Res Commun. 2026;814:153669.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. DE MOURA ACC, Rizzo A, Santos TAB, Olivato GB, et al
   Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15893.
   PubMed        
   
   
8. CHANG PY, Chiou WR
   Efficiency and safety of a guidewire-less approach to superselective transarterial microcatheter procedures in hepatic cancer interventions.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15907.
   PubMed        
   
   

   
   BMC Gastroenterol

9. SARTINI C, Herrera R, Mazhar F, Torres ZA, et al
   Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.
   BMC Gastroenterol. 2026 Mar 26. doi: 10.1186/s12876-026-04745.
   PubMed        
   
   

   
   Cancer Res

10. HAN L, Huo Y, Yang Y, Zhang L, et al
    The tRNA-Derived Fragment tRF-E Promotes Ferroptosis in Hepatocellular Carcinoma to Suppress Tumor Progression.
    Cancer Res. 2026 Mar 26. doi: 10.1158/0008-5472.CAN-25-2492.
    PubMed         Abstract available
    
    

    
    Eur J Pediatr

11. YIN T, Liu W, Chen X, Chen S, et al
    Pathological analysis of liver and cyst wall in prenatally diagnosed choledochal cysts in children.
    Eur J Pediatr. 2026;185:214.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. TAO X, Jiang W, Tang H
    A Mysterious Case of Diffuse Severe Hepatic Steatosis in a Thin Teenager.
    Gastroenterology. 2026 Mar 23:S0016-5085(26)00255.
    PubMed        
    
    
13. MULLISH BH, Mullish BH
    Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis.
    Gastroenterology. 2026 Mar 23:S0016-5085(26)00256.
    PubMed        
    
    
14. LOOMBA R, Clark VC, Mandorfer M, Miravitlles M, et al
    Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.
    Gastroenterology. 2026;170:829-842.
    PubMed         Abstract available
    
    
15. TORP N, Johansen S, Jensen EL, Maagaard M, et al
    Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.
    Gastroenterology. 2026;170:803-814.
    PubMed         Abstract available
    
    
16. CARTER JA, Dickerson LK, Stephanou A, Damle SR, et al
    Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.
    Gastroenterology. 2026;170:787-802.
    PubMed         Abstract available
    
    

    
    Hepatology

17. LIANG Z, Jin H, Gao W, Hu X, et al
    Prospective head-to-head comparison of routine non-invasive scores for predicting severe cirrhosis-related morbidity in the general population.
    Hepatology. 2026 Mar 23. doi: 10.1097/HEP.0000000000001749.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

18. BISWAS S, Madhusudhan KS, Shalimar
    Challenges in the management of vascular liver disorders in women in the reproductive period.
    Indian J Gastroenterol. 2026;45:178-191.
    PubMed         Abstract available
    
    
19. KOSUTA I, Kozina L, Cizmic P, Kosuta L, et al
    Non-invasive liver fibrosis screening and referral patterns in women with dependence due to psychoactive substance use: A single-centre retrospective study.
    Indian J Gastroenterol. 2026;45:259-267.
    PubMed         Abstract available
    
    
20. PENMETSA R, Kapil S, VanWagner LB
    Sex and gender differences in metabolic dysfunction-associated liver disease.
    Indian J Gastroenterol. 2026;45:192-201.
    PubMed         Abstract available
    
    
21. GOVALAN R, Singh S, Sharma P
    Gender disparities in liver transplantation.
    Indian J Gastroenterol. 2026;45:202-210.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

22. ZHANG F, Wang YS, Liu LX, Wang JZ, et al
    Reply to "Checking the shape of hepatocellular carcinoma: How irregular is irregular?".
    J Gastroenterol. 2026 Mar 21. doi: 10.1007/s00535-026-02394.
    PubMed        
    
    
23. ONO A, Miura R, Hayes CN, Kawaoka T, et al
    Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".
    J Gastroenterol. 2026 Mar 25. doi: 10.1007/s00535-026-02390.
    PubMed        
    
    

    
    J Gastroenterol Hepatol

24. CHAN LL, Chan KOK, Chan SL
    Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70354.
    PubMed         Abstract available
    
    
25. WU F, Guo Z, Guan J, Xu J, et al
    IL-15 Plus Thymosin alpha1 Reduces Senescent Hepatic CD8(+) T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70359.
    PubMed         Abstract available
    
    
26. KIM MN
    Reply Letter to: A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 25. doi: 10.1111/jgh.70335.
    PubMed        
    
    
27. KHAN T, Rizvi AR, Ahmad R, Saqib HW, et al
    Enhancing Prognostication in Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Beyond Baseline ALBI Grade.
    J Gastroenterol Hepatol. 2026 Mar 22. doi: 10.1111/jgh.70355.
    PubMed        
    
    

    
    J Hepatol

28. WOLF C, Lange K, Stallmach A, Tannapfel A, et al
    Corrigendum to: "A rare vascular puzzle: Portal hypertension and hepatic lesions" [J Hepatol (2026) 84: e59-61].
    J Hepatol. 2026 Mar 25:S0168-8278(26)00125-X. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
29. BALLESTER MP, Gallego-Duran R, Shalimar, Thomsen KL, et al
    Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN.
    J Hepatol. 2026 Mar 20:S0168-8278(26)00146-7. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    

    
    N Engl J Med

30. 
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    N Engl J Med. 2026;394:1248.
    PubMed        
    
    

    
    Oncogene

31. DENG R, Zheng X, Liu F, Gao J, et al
    The NPC1/USP7/p53 axis regulates cholesterol and promotes the proliferation of hepatocellular carcinoma.
    Oncogene. 2026 Mar 26. doi: 10.1038/s41388-026-03739.
    PubMed         Abstract available
    
    

    
    PLoS One

32. KOSITAMONGKOL C, Tantiyavarong P, Ratanatawan A, Sripongpun P, et al
    Cost-utility and budget impact analyses of significant fibrosis detection in individuals with metabolic syndrome or obesity in Thailand.
    PLoS One. 2026;21:e0344985.
    PubMed         Abstract available
    
    
33. FUDEYASU K, Asaeda M, Kawae T, Nomura T, et al
    Association between diabetes mellitus and impaired single-leg stance in patients with chronic liver disease: A cross-sectional study.
    PLoS One. 2026;21:e0345407.
    PubMed         Abstract available
    
    
34. RADHA R, Anjum S, Abusamra RH, Paul V, et al
    Ultrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy.
    PLoS One. 2026;21:e0345161.
    PubMed         Abstract available
    
    

    
    Radiology

35. CENTNER CS, Choi R, Georgiades CS, Yarchoan M, et al
    Thermal and Nonthermal Liver Ablation: Mechanistic Foundations, Clinical Implementation, Immunologic Trial Design, and Artificial Intelligence.
    Radiology. 2026;318:e250263.
    PubMed         Abstract available
    
    
36. DIMOPOULOS MP, Sotirchos VS, Vakiani E, Sigel C, et al
    Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial).
    Radiology. 2026;318:e250864.
    PubMed         Abstract available
    
    
37. DOPPELT G, Occean BV, Fabbro-Peray P, Haefliger L, et al
    The Safety Standards for Liver Percutaneous Thermal Ablation: A Meta-Analysis of Adverse Events over 15 Years.
    Radiology. 2026;318:e251517.
    PubMed         Abstract available
    
    

    
    Semin Liver Dis

38. SU F, Torres-Hernandez A, Hickey R, Shanbhogue K, et al
    Expert Practical Recommendations for Hepatocellular Carcinoma.
    Semin Liver Dis. 2026 Mar 25. doi: 10.1055/a-2832-4720.
    PubMed         Abstract available
    
    

    
    Transplant Proc

39. CHEN H, Zhang H, Guo S, Li J, et al
    Prolonged Prothrombin Time: A Reliable Clinical Indicator of Therapeutic Efficacy for Chronic Liver Failure Treated With Artificial Liver Support System.
    Transplant Proc. 2026;58:520-525.
    PubMed         Abstract available
    
    
40. LAREDO JA, Konakalla P, Khalil M, Helmick RA, et al
    Fixed Versus Growth Mindset and the Association With Alcohol Relapse After Liver Transplantation.
    Transplant Proc. 2026 Feb 26:S0041-1345(26)00087.
    PubMed         Abstract available
    
    
41. CHEN C, Zheng Q, Zhang L, Guo Q, et al
    Peptide Receptor Radionuclide Therapy for Recurrent Neuroendocrine Tumor Liver Metastases After Liver transplantation: A Case Series.
    Transplant Proc. 2026 Feb 26:S0041-1345(26)00100.
    PubMed         Abstract available
    
    

    
    Transplantation

42. MENG Q, Chen H, Li J, Qin M, et al
    Ischemia-free Liver Transplantation: 7-y Experience From a Single-center Cohort in China.
    Transplantation. 2025 Dec 2. doi: 10.1097/TP.0000000000005555.
    PubMed         Abstract available
    
    
43. NAKAYAMA T, Esquivel CO, Melcher ML, Sasaki K, et al
    Survival Benefit of Accepting Livers From Donation After Circulatory Death Donors Older Than or Equal to 60 y in the United States.
    Transplantation. 2026;110:e856-e865.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum